Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Ferguson

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Nature Cancer|December 11, 2020
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Nature Communications|April 8, 2024
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanomaXinyu Bai, Grace H Attrill, Tuba N Gide, et al.
Journal of the American Academy of Dermatology|October 29, 2025
In vivo cutaneous confocal microscopy for diagnosing the lentigo maligna spectrum: A multicentre prospective study and proposal of a lentigo maligna spectrum scoreBruna Melhoranse Gouveia, Terence Wong, Peter M Ferguson, et al.
BMJ Open|January 14, 2025
Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised studyZhuohan Wu, Brooke Nickel, Farzaneh Boroumand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain MetastasesJames S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
Cancer Immunology Research|September 12, 2020
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous MelanomasJarem Edwards, Peter M Ferguson, Serigne N Lo, et al.
Oncoimmunology|February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patientsHansol Lee, Camelia Quek, Ines Silva, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Organic & Biomolecular Chemistry|January 19, 2019
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonistBenjamin J Compton, Kathryn J Farrand, Ching-Wen Tang, et al.
The British Journal of Dermatology|October 11, 2024
Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcomaLouise van der Weyden, Martin Del Castillo Velasco-Herrera, Saamin Cheema, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Nature Cancer|December 11, 2020
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Nature Communications|April 8, 2024
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanomaXinyu Bai, Grace H Attrill, Tuba N Gide, et al.
Journal of the American Academy of Dermatology|October 29, 2025
In vivo cutaneous confocal microscopy for diagnosing the lentigo maligna spectrum: A multicentre prospective study and proposal of a lentigo maligna spectrum scoreBruna Melhoranse Gouveia, Terence Wong, Peter M Ferguson, et al.
BMJ Open|January 14, 2025
Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised studyZhuohan Wu, Brooke Nickel, Farzaneh Boroumand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain MetastasesJames S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
Cancer Immunology Research|September 12, 2020
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous MelanomasJarem Edwards, Peter M Ferguson, Serigne N Lo, et al.
Oncoimmunology|February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patientsHansol Lee, Camelia Quek, Ines Silva, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Organic & Biomolecular Chemistry|January 19, 2019
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonistBenjamin J Compton, Kathryn J Farrand, Ching-Wen Tang, et al.
The British Journal of Dermatology|October 11, 2024
Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcomaLouise van der Weyden, Martin Del Castillo Velasco-Herrera, Saamin Cheema, et al.
Pageof 5